Full and broad-spectrum in vivo eradication of catheter-associated biofilms using gentamicin-EDTA antibiotic lock therapy

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6310-6318

  Chauhan, Ashwini ^a   Lebeaux, David ^a   Ghigo, Jean Marc ^a   Beloin, Christophe ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EDETIC ACID; GENTAMICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BIOFILM; CATHETER INFECTION; CONTROLLED STUDY; ERADICATION THERAPY; ESCHERICHIA COLI; IN VIVO STUDY; INFECTION PREVENTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT DURATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BIOFILMS; CATHETER-RELATED INFECTIONS; CATHETERS; EDETIC ACID; GENTAMICINS; GRAM-NEGATIVE BACTERIA; IMMUNOSUPPRESSION; LENGTH OF STAY; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RATS; RATS, SPRAGUE-DAWLEY; STAPHYLOCOCCUS AUREUS;

EID: 84869217998     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01606-12     Document Type: Article

References (55)

1. Ahmad NM, Rojtman AD. 2010. Successful treatment of daptomycin- nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin. Ann. Pharmacother. 44:918-921.
2. Allon M. 2007. Current management of vascular access. Clin. J. Am. Soc. Nephrol. 2:786-800.
3. Betjes MG, van Agteren M. 2004. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol. Dial. Transplant. 19:1546-1551.
4. Bleyer AJ, Mason L, Russell G, Raad II, Sherertz RJ. 2005. A randomized, controlled trial of a new vascular catheter flush solution (minocycline-EDTA) in temporary hemodialysis access. Infect. Control Hosp. Epidemiol. 26:520-524.
5. Blot SI, et al. 2005. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin. Infect. Dis. 41:1591-1598.
6. Bookstaver PB, Williamson JC, Tucker BK, Raad II, Sherertz RJ. 2009. Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections. Ann. Pharmacother. 43:210-219.
7. Carratala J, et al. 1999. Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob. Agents Chemother. 43:2200-2204.
8. Chang L, Tsai JS, Huang SJ, Shih CC. 2003. Evaluation of infectious complications of the implantable venous access system in a general oncologic population. Am. J. Infect. Control 31:34-39.
9. Chauhan A, et al. 2012. A rat model of central venous catheter to study establishment of long-term bacterial biofilm and related acute and chronic infections. PLoS One 7:e37281. doi:10.1371/journal.pone.0037281.
10. CLSI. 2009. Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eighth edition. CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Console G, et al. 2007. Clinical and economic effects of central venous catheters on oncology patient care. J. Chemother. 19:309-314.
12. Dannenberg C, Bierbach U, Rothe A, Beer J, Korholz D. 2003. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. J. Pediatr. Hematol. Oncol. 25:616-621.
13. Darouiche RO. 2004. Treatment of infections associated with surgical implants. N. Engl. J. Med. 350:1422-1429.
14. Del Pozo JL, et al. 2009. Effectiveness of teicoplanin versus vancomycin lock therapy in the treatment of port-related coagulase-negative staphylococci bacteraemia: a prospective case-series analysis. Int. J. Antimicrob. Agents 34:482-485.
15. Donlan RM. 2002. Biofilms: microbial life on surfaces. Emerg. Infect. Dis. 8:881-890.
16. Droste JC, Jeraj HA, MacDonald A, Farrington K. 2003. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J. Antimicrob. Chemother. 51:849-855.
17. Fernandez-Hidalgo N, et al. 2006. Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study. J. Antimicrob. Chemother. 57:1172-1180.
18. Fortun J, et al. 2006. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy. J. Antimicrob. Chemother. 58:816-821.
19. Foucault M-L, Thomas L, Goussard S, Branchini BR, Grillot-Courvalin C. 2010. In vivo bioluminescence imaging for the study of intestinal colonization by Escherichia coli in mice. Appl. Environ. Microbiol. 76:264-274.
20. Fowler VG, Jr, et al. 2005. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40:695-703.
21. Funalleras G, et al. 2011. Effectiveness of antibiotic-lock therapy for long-term catheter-related bacteremia due to Gram-negative bacilli: a prospective observational study. Clin. Infect. Dis. 53:e129-e132.
22. Ghannoum MA, Isham N, Jacobs MR. 2011. Antimicrobial activity of B-Lock against bacterial and Candida spp. causing catheter-related bloodstream infections. Antimicrob. Agents Chemother. 55:4430-4431.
23. Hulten KG, et al. 2010. Hospital-acquired Staphylococcus aureus infections at Texas Children's Hospital, 2001-2007. Infect. Control Hosp. Epidemiol. 31:183-190.
24. Jones BA, et al. 2010. Efficacy of ethanol locks in reducing central venous catheter infections in pediatric patients with intestinal failure. J. Pediatr. Surg. 45:1287-1293.
25. Lafrance JP, et al. 2010. Vascular access-related bloodstream infections in First Nations, community and teaching Canadian dialysis units, and other centre-level predictors. Nephron Clin. Pract. 114:c204-c212.
26. Lewis K. 2007. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 5:48-56.
27. Lewis K. 2001. Riddle of biofilm resistance. Antimicrob. Agents Chemother. 45:999-1007.
28. Mack D, et al. 2002. Differential expression of methicillin resistance by different biofilm-negative Staphylococcus epidermidis transposon mutant classes. Antimicrob. Agents Chemother. 46:178-183.
29. Maki DG, Kluger DM, Crnich CJ. 2006. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin. Proc. 81:1159-1171.
30. McIntyre CW, Hulme LJ, Taal M, Fluck RJ. 2004. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int. 66:801-805.
31. Mermel LA, et al. 2009. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49:1-45.
32. O'Grady NP. 2002. Applying the science to the prevention of catheter-related infections. J. Crit. Care 17:114-121.
33. Oliveira C, Nasr A, Brindle M, Wales PW. 2012. Ethanol locks to prevent catheter-related bloodstream infections in parenteral nutrition: a meta-analysis. Pediatrics 129:318-329.
34. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. 2010. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob. Agents Chemother. 54:4329-4334.
35. Raad II, et al. 2008. The role of chelators in preventing biofilm formation and catheter-related bloodstream infections. Curr. Opin. Infect. Dis. 21:385-392.
36. Raad II, et al. 2008. Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against Candida embedded in biofilm. Int. J. Antimicrob. Agents 32:515-518.
37. Raad II, et al. 1994. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 271:1014-1016.
38. Raad I. 1998. Intravascular-catheter-related infections. Lancet 351:893-898.
39. Raad I, Hanna H, Dvorak T, Chaiban G, Hachem R. 2007. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob. Agents Chemother. 51:78-83.
40. Ramphal R, et al. 2008. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J. Immunol. 181:586-592.
41. Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, Stas M, Peetermans WE. 2005. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J. Antimicrob. Chemother. 55:90-94.
42. Scott RD. 2009. The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/hai/pdfs/hai/scott- costpaper.pdf.
43. Seifert H. 1997. Catheter-related infections due to gram-negative bacilli, p 255-284. In Seifert H, Jansen B, Farr BM (ed), Catheter-related infections. Marcel Dekker, New York, NY.
44. Shanks RM, Sargent JL, Martinez RM, Graber ML, O'Toole GA. 2006. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol. Dial. Transplant. 21:2247-2255.
45. Stewart PS, Costerton JW. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138.
46. Sydnor ER, Perl TM. 2011. Hospital epidemiology and infection control in acute-care settings. Clin. Microbiol. Rev. 24:141-173.
47. Timsit JF, et al. 2011. New challenges in the diagnosis, management, and prevention of central venous catheter-related infections. Semin. Respir. Crit. Care Med. 32:139-150.
48. Tyler LS, Rehder TL, Davis RB. 1981. Effect of gentamicin on heparin activity. Am. J. Hosp. Pharm. 38:537-540.
49. Vandijck DM, et al. 2008. Daily cost of antimicrobial therapy in patients with intensive care unit-acquired, laboratory-confirmed bloodstream infection. Int. J. Antimicrob. Agents 31:161-165.
50. Van Praagh AD, et al. 2011. Daptomycin antibiotic lock therapy in a rat model of staphylococcal central venous catheter biofilm infections. Antimicrob. Agents Chemother. 55:4081-4089.
51. Venkatesh M, Rong L, Raad I, Versalovic J. 2009. Novel synergistic antibiofilm combinations for salvage of infected catheters. J. Med. Microbiol. 58:936-944.
52. Vescia S, et al. 2008. Management of venous port systems in oncology: a review of current evidence. Ann. Oncol. 19:9-15.
53. Vuong C, Kocianova S, Yu J, Jagath Kadurugamuwa L, Otto M. 2008. Development of real-time in vivo imaging of device-related Staphylococcus epidermidis infection in mice and influence of animal immune status on susceptibility to infection. J. Infect. Dis. 198:258-261.
54. Weijmer MC, et al. 2005. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J. Am. Soc. Nephrol. 16:2769-2777.
55. Zuluaga AF, Agudelo M, Cardeno JJ, Rodriguez CA, Vesga O. 2010. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model. PLoS One 5:e10744. doi:10.1371/journal.pone.0010744.